These findings led to the development of a specific BCL2 inhibitor (Venetoclax, AbbVie Inc., Chicago, IL, USA) that has now approved by the FDA for CLL, small lymphocytic lymphoma (SLL) and acute myeloid leukemia (AML) treatment. The gene discussed is BCL2; the disease is acute myeloid leukemia.